Status and phase
Conditions
Treatments
About
Determine the effect of Coenzyme Q10 on random blood sugar and glycosylated haemoglobin
Full description
Type 1 diabetes mellitus is an autoimmune disease that leads to destruction of insulin producing pancreatic Beta cells.
Individuals with type 1 diabetes requires life long insulin replacement with multiple daily insulin injection. daily,insulin pump therapy or the use of an automated insulin delivery system.
without insulin ,diabetic ketoacidosis develops and is life threatening.
In addition to insulin Therapy ,glucose monitoring with a continuous glucose monitor and a blood glucose monitor if continuous glucose monitor is unavailable is recommended .
Coenzyme Q10 supplementation has beneficial effects on glycemic control especially in diabetes , and 100-200 mg per day of Co Q10 could achieve the greatest benefit which could provide a basis for the dietary guidelines of Co Q10 in patients with glycemic disorders .
Co Q10 with a known antiinflammatory and antioxidant has beneficial effects on endothelial function and therefore minimize the microvascular and macrovascular complication in patients with type 1 diabetes mellitus.
Administration of Co Q10 for 3 months in type 1 diabetes mellitus in pediatric patients was will tolerated but had no favorable effect on endothelial dysfunction or metabolic parameters .
Co Q10 in addition to improving the metabolic hyperglycemia , it improve Hb A1c and the lipid profile.
patients with type 1 diabetes , especially poorly controlled had elevation of plasma vitamin E and coenzyme Q10 levels and decreased platelet redox status of coenzyme Q10 which may be an indicator of increased oxidative stress ,so Co Q10 has an antioxidant effects.
Researches on this topic are limited on pediatrics and investigators search for it and will see the result.(clinical trial)
Co Q10 is present in the forms of soft gel capsules ,oral spray , hard gel capsules and tablets .
Co Q10 approved from age of 2 years old to 18 years old .
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Faisal Alkhateeb Ahmad Abdullah, Professor; Christina Saad Abdel Malak Abdel Nour
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal